Clinical trials: Lenalidomide, open to volunteers
Follicular Lymphomas
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
Primary Objective: To compare the complete response rate (CR rate) after induction treatment between the ZR2 regimen and the R2 regimen.<br/><br/>Secondary Objectives: To compare the objective response rate (ORR) after induction…
- Trial name
- NCT07505849
- Testing
- Zanubrutinib+R2, R2
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KeshuZhou
Cognitive Impairment, Mild, Cognitive Dysfunction
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as…
- Conditions
- Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegenerative Disease, Hereditary
- Trial name
- NCT06177028
- Testing
- Lenalidomide 10 mg
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Myeloma Multiple
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
- Trial name
- NCT05091372
- Testing
- Belantamab mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center